Oncology
Ultimovacs downsizes to funnel funds to cancer vaccine programme
Ultimovacs has implemented cash-saving strategies, including a 40% workforce reduction, to extend its reserves into Q4 2025. The operational adjustments…
Volastra Therapeutics initiates dosing in Phase Ib ovarian cancer trial
Volastra Therapeutics has announced the dosing of the first subject in a Phase Ib clinical trial of sovilnesib for patients…
AstraZeneca’s Imfinzi shows overall survival benefit in Phase III BTC trial
AstraZeneca has announced updated exploratory results from the TOPAZ-1 Phase III clinical trial, indicating that Imfinzi (durvalumab) plus standard-of-care chemotherapy…
Sanofi advances NK cell engager to Phase II for blood cancer treatment
Sanofi has moved its natural killer (NK) cell engager candidate SAR443579/IPH6101 to a Phase II trial evaluating the drug’s use…
Roche’s Columvi offers survival benefit in Phase III DLBCL trial
Roche has released data from the Phase III STARGLO trial where its therapy Columvi (glofitamab) plus gemcitabine plus oxaliplatin (GemOx)…
QUT and Omico partner to offer cancer treatment trials in Australia
The Queensland University of Technology’s (QUT) ATGC has entered into a partnership with non-profit research organisation Omico and the PrOSPeCT…
Pipeline Moves: Pfizer’s flu vaccine approval chances rise after Phase III completion
This week on Pipeline Moves, we kick off by looking at a Phase III trial completion of Pfizer’s influenza vaccine…
Candel wins FDA orphan drug designation for pancreatic cancer drug
The US Food and Drug Administration (FDA) has granted Candel Therapeutics’ immunotherapy candidate CAN-2409 (aglatimagene besadenovec) orphan drug designation for…
Boundless Bio doses first subject in advanced cancer treatment trial
Boundless Bio has dosed the first subject in the Phase I/II STARMAP clinical trial of BBI-825 aimed at treating individuals…
FDA approval makes Enhertu an option for multiple tumour indications
On 5 April 2024, Daiichi Sankyo and AstraZeneca’s HER2-targeting antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) received accelerated approval to treat…